Associated Papers
RAC2 gain-of-function variants causing inborn error of immunity drive NLRP3 inflammasome activation.
Doye A et al.
The Journal of Experimental Medicine, 2024
Hyperactive Rac stimulates cannibalism of living target cells and enhances CAR-M-mediated cancer cell killing.
Mishra AK et al.
Proceedings of the National Academy of Sciences of the United States of America, 2023
Combined Immunodeficiency Caused by a Novel De Novo Gain-of-Function RAC2 Mutation.
Zhang L et al.
Journal of Clinical Immunology, 2022
A gain-of-function RAC2 mutation is associated with bone-marrow hypoplasia and an autosomal dominant form of severe combined immunodeficiency.
Lagresle-Peyrou C et al.
Haematologica, 2021
The molecular basis for immune dysregulation by the hyperactivated E62K mutant of the GTPase RAC2.
Arrington ME et al.
The Journal of Biological Chemistry, 2020
A monoallelic activating mutation in RAC2 resulting in a combined immunodeficiency.
Lougaris V et al.
The Journal of Allergy and Clinical Immunology, 2019
Juvenile myelomonocytic leukemia displays mutations in components of the RAS pathway and the PRC2 network.
Caye A et al.
Nature Genetics, 2015
KRAS codon 12 and 13 mutations in relation to disease-free survival in BRAF-wild-type stage III colon cancers from an adjuvant chemotherapy trial (N0147 alliance).
Yoon HH et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2014
The proto-oncogene KRAS and BRAF profiles and some clinical characteristics in colorectal cancer in the Turkish population.
Ozen F et al.
Genetic Testing and Molecular Biomarkers, 2013
Detecting KRAS mutations in peripheral blood of colorectal cancer patients by peptide nucleic acid clamp PCR.
Miyano S et al.
Experimental and Therapeutic Medicine, 2012
Impact of the specific mutation in KRAS codon 12 mutated tumors on treatment efficacy in patients with metastatic colorectal cancer receiving cetuximab-based first-line therapy: a pooled analysis of three trials.
Modest DP et al.
Oncology, 2012
Detection of KRAS and BRAF mutations in colorectal carcinoma roles for high-sensitivity locked nucleic acid-PCR sequencing and broad-spectrum mass spectrometry genotyping.
Arcila M et al.
The Journal of Molecular Diagnostics : Jmd, 2011
KRAS mutations in Slovene patients with colorectal cancer: frequency, distribution and correlation with the response to treatment.
Licar A et al.
International Journal of Oncology, 2010
Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer.
Neumann J et al.
Pathology, Research and Practice, 2009
K-ras mutations and benefit from cetuximab in advanced colorectal cancer.
Karapetis CS et al.
The New England Journal of Medicine, 2008
Fluoride complexes of oncogenic Ras mutants to study the Ras-RasGap interaction.
Gremer L et al.
Biological Chemistry, 2008
Ras superfamily monomeric G proteins in carcinoma cell motility.
Oxford G et al.
Cancer Letters, 2003
RGS14 is a novel Rap effector that preferentially regulates the GTPase activity of galphao.
Traver S et al.
The Biochemical Journal, 2000
Mutant Rac1B expression in Dictyostelium: effects on morphology, growth, endocytosis, development, and the actin cytoskeleton.
Palmieri SJ et al.
Cell Motility and the Cytoskeleton, 2000